JP2023503465A5 - - Google Patents

Info

Publication number
JP2023503465A5
JP2023503465A5 JP2022530662A JP2022530662A JP2023503465A5 JP 2023503465 A5 JP2023503465 A5 JP 2023503465A5 JP 2022530662 A JP2022530662 A JP 2022530662A JP 2022530662 A JP2022530662 A JP 2022530662A JP 2023503465 A5 JP2023503465 A5 JP 2023503465A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
cycloalkyl
group
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022530662A
Other languages
English (en)
Japanese (ja)
Other versions
JP7691753B2 (ja
JP2023503465A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/061158 external-priority patent/WO2021105908A1/en
Publication of JP2023503465A publication Critical patent/JP2023503465A/ja
Publication of JP2023503465A5 publication Critical patent/JP2023503465A5/ja
Application granted granted Critical
Publication of JP7691753B2 publication Critical patent/JP7691753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022530662A 2019-11-25 2020-11-25 ベータ-グルコセレブロシダーゼの活性の変質に関連する状態におけるヘテロアリール化合物およびその治療的使用 Active JP7691753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19383037.9 2019-11-25
EP19383037 2019-11-25
PCT/IB2020/061158 WO2021105908A1 (en) 2019-11-25 2020-11-25 Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase

Publications (3)

Publication Number Publication Date
JP2023503465A JP2023503465A (ja) 2023-01-30
JP2023503465A5 true JP2023503465A5 (cg-RX-API-DMAC10.html) 2023-11-17
JP7691753B2 JP7691753B2 (ja) 2025-06-12

Family

ID=68808239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530662A Active JP7691753B2 (ja) 2019-11-25 2020-11-25 ベータ-グルコセレブロシダーゼの活性の変質に関連する状態におけるヘテロアリール化合物およびその治療的使用

Country Status (10)

Country Link
US (1) US12661342B2 (cg-RX-API-DMAC10.html)
EP (1) EP4065563A1 (cg-RX-API-DMAC10.html)
JP (1) JP7691753B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220150878A (cg-RX-API-DMAC10.html)
CN (1) CN115348959B (cg-RX-API-DMAC10.html)
AU (1) AU2020394602B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022010126A2 (cg-RX-API-DMAC10.html)
IL (1) IL293309B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022006065A (cg-RX-API-DMAC10.html)
WO (1) WO2021105908A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023418678A1 (en) 2022-12-30 2025-07-17 Gt Gain Therapeutics Sa Method of treating tauopathies
WO2025221055A1 (ko) * 2024-04-18 2025-10-23 에스케이바이오팜 주식회사 유레아 화합물 및 이의 용도
WO2026134316A1 (ja) * 2024-12-20 2026-06-25 アステラス製薬株式会社 ヘテロアリールアミド化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052988A (cg-RX-API-DMAC10.html) * 1962-07-03
ES2273047T3 (es) * 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US20180092923A1 (en) * 2015-04-15 2018-04-05 Biomarin Pharmaceutical Inc. Methods for treating lysosomal storage disorders
BR112019013571A2 (pt) 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use

Similar Documents

Publication Publication Date Title
EP2447253B1 (en) Dihydropyrimidine compounds, preparation methods, pharmaceutical compositions thereof and their use as antiviral agents
IL322686A (en) Heterocyclic glp-1 agonists
JP2020519606A5 (cg-RX-API-DMAC10.html)
CN102112453A (zh) 新的钾通道阻断剂及其用途
JP2017525737A (ja) キノリノン系化合物及びその薬物への使用
US10479790B2 (en) COMT inhibiting methods and compositions
JP2020504122A5 (cg-RX-API-DMAC10.html)
JP2019501919A (ja) スルファミド誘導体およびその製造方法と応用
KR20150103034A (ko) 피리돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도
JP4285723B2 (ja) 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体
JP2021509907A (ja) アセタール化合物およびその治療的使用
JPWO2001036402A1 (ja) 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体
US20170197981A1 (en) Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
JP6310923B2 (ja) ジヒドロピリミジン誘導体の結晶形
TNSN05080A1 (en) NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published)
JP2022519764A (ja) 二環式スルホンアミド
JP5876885B2 (ja) ニトロベンゾチアゾール誘導体および結核治療のためのこれらの使用
CA2398186A1 (en) Therapeutic agent for reperfusion injury comprising integrin .alpha.v.beta.3 antagonists
US9126989B2 (en) Compound and methods for treating long QT syndrome
US20230019280A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP2023503470A5 (cg-RX-API-DMAC10.html)
JP2020514284A5 (cg-RX-API-DMAC10.html)
CS277691A3 (en) 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments
KR20180112773A (ko) 인돌리진 유도체, 조성물 및 사용 방법
JP7862858B2 (ja) Mps1を処置するための併用療法